Core Insights - Zentalis Pharmaceuticals has initiated dosing for the first patient in Part 2 of the Phase 2 DENALI clinical trial for azenosertib, targeting Cyclin E1+ platinum-resistant ovarian cancer [1][3] - The company anticipates topline data from DENALI Part 2 by the end of 2026, which could support accelerated approval from the FDA [2][3] - Azenosertib is a novel WEE1 inhibitor being evaluated as a monotherapy and in combination therapies across multiple tumor types [5][6] Clinical Trial Details - The DENALI trial is designed in two parts, with seamless enrollment; Part 2a aims to confirm the primary dose of azenosertib with approximately 30 patients at two dose levels: 400mg QD 5:2 and 300mg QD 5:2 [7] - Part 2b will enroll around 70 additional patients based on the results from Part 2a, pending FDA feedback [7] Clinical Data and Biomarkers - Previous data from Part 1b of the DENALI study indicated an objective response rate (ORR) of 34.9% among 43 response-evaluable patients, with a median duration of response (mDOR) of 6.3 months [3][4] - Cyclin E1 protein overexpression has been identified as a predictive biomarker for patient selection, with an estimated 50% of PROC patients overexpressing this protein [4] Company Overview - Zentalis Pharmaceuticals is focused on developing azenosertib as a potentially first-in-class and best-in-class treatment for Cyclin E1+ PROC, with ongoing research into additional applications [6] - The company has demonstrated that azenosertib is well tolerated and shows anti-tumor activity across various tumor types [6]

Core Viewpoint - Zentalis Pharmaceuticals is advancing its clinical-stage biopharmaceutical development of azenosertib, a WEE1 inhibitor, with a poster presentation scheduled at the 2025 ASCO Annual Meeting, showcasing its potential in treating metastatic colorectal cancer and other tumor types [1][2][4]. Company Overview - Zentalis Pharmaceuticals, Inc. is focused on developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor targeting Cyclin E1+ platinum-resistant ovarian cancer and other tumor types [4]. - The company is conducting clinical trials to evaluate azenosertib both as a monotherapy and in combination therapies, demonstrating anti-tumor activity and good tolerability across various cancer types [4]. Clinical Trial Details - An abstract has been accepted for a poster presentation at the 2025 ASCO Annual Meeting, detailing the Phase 1/2 clinical trial results of azenosertib in combination with encorafenib and cetuximab for patients with metastatic BRAF V600E mutant colorectal cancer [2]. - The poster presentation is scheduled for May 31, 2025, and will include clinical data up to an April 4, 2025 cutoff [2]. Mechanism of Action - Azenosertib functions as a selective and orally bioavailable WEE1 inhibitor, which regulates the G1-S and G2-M cell cycle checkpoints, allowing for cell cycle progression despite DNA damage, ultimately leading to cancer cell death [3].

Core Insights - Zentalis Pharmaceuticals is presenting updated clinical data from the ongoing Phase 2 DENALI trial of azenosertib for patients with platinum-resistant ovarian cancer (PROC) at the SGO 2025 Annual Meeting [1] - Azenosertib is a potentially first-in-class WEE1 inhibitor being evaluated as a monotherapy and in combination across multiple tumor types, showing anti-tumor activity and good tolerability in clinical trials [2] Company Overview - Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing azenosertib (ZN-c3) for Cyclin E1+ platinum-resistant ovarian cancer [2] - The company is leveraging its expertise to explore additional research opportunities for azenosertib beyond PROC [2] Presentation Details - The oral presentation titled "Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes from Part 1b of the DENALI Study (GOG-3066)" will be presented by Dr. Fiona Simpkins on March 15 [4] - A poster presentation on the synergistic antitumor effects of azenosertib with microtubule inhibitor-based ADCs will be presented by Dr. Joanna Guo on March 16 [4]